Copyright
©The Author(s) 2023.
World J Gastrointest Endosc. Mar 16, 2023; 15(3): 133-145
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.133
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.133
Table 1 Anterograde and retrograde bowel preparation regimens studied in patients with inflammatory bowel disease
Ref. | Year | Design | n | IBD | Bowel preparation | Split dosing considered | Low fiber diet considered | Main result (success), % | Post-colonoscopy IBD flare-up rate, % (days after colonoscopy) | Severe AEs |
Gould et al[13] | 1982 | CT | 23 | UC: 23 | Castor oil 30 mL | - | YES | 82.6 | 26 (14-21 d) | NO |
Gould et al[13] | 1982 | CT | 23 | UC: 23 | Sennosides 75 mg | - | YES | 86.9 | 48 (14-21 d) | NO |
Lazzaroni et al[15] | 1993 | CT | 48 | UC: 26; CD: 23 | 4 L PEG-ELS plus placebo | YES | - | 96 | - | NO |
Lazzaroni et al[15] | 1993 | CT | 57 | UC: 35; CD: 21 | 4 L PEG-ELS plus simethicone | YES | - | 96 | - | NO |
Manes et al[53] | 2015 | CT | 106 | UC: 106 | 2 L PEG plus bisacodyl | YES | YES | 83 | - | NO |
Manes et al[53] | 2015 | CT | 105 | UC: 105 | 4 L PEG-ELS | YES | YES | 77.1 | - | NO |
Kim et al[22] | 2017 | CT | 53 | UC: 53 | 4 L PEG-ELS | YES | YES | 96.2 | 5.7 (7 d); 1.9 (28 d) | NO |
Kim et al[22] | 2017 | CT | 56 | UC: 56 | 2 L PEG plus ascorbate | YES | YES | 92.9 | 3.6 (7 d); 1.8 (28 d) | NO |
Briot et al[31] | 2019 | nCT Prospective | UC: 21; CD: 57; Unspecified IBD: 2 | Picosulphate-based regimen | YES | YES | 78.4 | 0 | NO | |
Bezzio et al[39] | 2020 | nCTProspective | 189 | UC: 63; CD: 63 | 2 L PEG-ELS plus simethicone | YES | - | UC: 89.8; CD: 86.2 | - | NO |
Maida et al[25] | 2021 | nCT Retrospective | 185 | UC: 95; CD: 90 | 1 L PEG plus ascorbate solution | YES | YES | 92.9 | - | NO |
Mohsen et al[30] | 2021 | CT | 61 | - | 2 L Sodium; picosulphate, magnesium citrate PEG | YES | YES | 89.5 | - | NO |
Mohsen et al[30] | 2021 | CT | 64 | - | 2 L PEG plus ascorbate solution | YES | YES | - | NO | |
Neri et al[29] | 2021 | nCT Prospective | 103 | UC: 47; CD: 56 | 1 L PEG-ELS | YES | YES | 85.4 | - | NO |
Kim et al[32] | 2022 | nCT Prospective | 52 | UC: 35; CD: 17 | 2 L PEG plus ascorbate | YES | YES | 98.1 | 0 (7 and 28 d) | NO |
Kim et al[32] | 2022 | nCT Prospective | 55 | UC: 37; CD: 18 | Novel oral sulphate tablets | YES | YES | 98.1 | 3,63 (7 and 28 d) | NO |
Gajera et al[51] | 2022 | nCT Retrospective | 318 | UC: 182; CD: 104; Unspecified IBD: 28 | Colonic lavage | Not applicable | YES | 97 | - | NO |
Table 2 Case reports on patients with known inflammatory bowel disease and relevant adverse events related to bowel preparation
Ref. | Bowel preparation | Age | IBD | Gender | AE | Comorbidity | IBD therapy | Outcome |
Loraine et al[34] | Sodium picosulphate/magnesium oxide/citric acid | 73 | CD | F | Shock | Severe COPD, hypertension, dyslipidemia, cardiomyopathy, diverticular disease | Azathioprine | Dead |
Gonlusen et al[35] | Sodium picosulphate | 56 | CD | F | Acute renal failure | GERD, healed gastric ulcer, endometriosis, mitral valve prolapse, migraine | None | Favourable |
- Citation: Gravina AG, Pellegrino R, Romeo M, Palladino G, Cipullo M, Iadanza G, Olivieri S, Zagaria G, De Gennaro N, Santonastaso A, Romano M, Federico A. Quality of bowel preparation in patients with inflammatory bowel disease undergoing colonoscopy: What factors to consider? World J Gastrointest Endosc 2023; 15(3): 133-145
- URL: https://www.wjgnet.com/1948-5190/full/v15/i3/133.htm
- DOI: https://dx.doi.org/10.4253/wjge.v15.i3.133